Howard Burris 3rd
Overview
Explore the profile of Howard Burris 3rd including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
970
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lakhani N, Burris 3rd H, Miller Jr W, Huang M, Chen L, Siu L
Invest New Drugs
. 2024 Sep;
42(5):581-589.
PMID: 39276176
Combining a checkpoint inhibitor with an inhibitor of extracellular signal-regulated kinase (ERK) may result in synergistic antitumor activity. We evaluated MK-8353, an ERK1 and ERK2 inhibitor, plus pembrolizumab in a...
2.
Johnson M, Wang J, Falchook G, Greenlees C, Jones S, Strickland D, et al.
Br J Cancer
. 2023 Mar;
128(10):1906-1915.
PMID: 36871042
Background: AZD2811 is a potent, selective Aurora kinase B inhibitor. We report the dose-escalation phase of a first-in-human study assessing nanoparticle-encapsulated AZD2811 in advanced solid tumours. Methods: AZD2811 was administered...
3.
McKenzie A, Dilks H, Jones S, Burris 3rd H
Expert Rev Mol Diagn
. 2019 Jan;
19(2):89-93.
PMID: 30618301
No abstract available.
4.
Perez E, Barrios C, Eiermann W, Toi M, Im Y, Conte P, et al.
J Clin Oncol
. 2017 Jan;
35(2):141-148.
PMID: 28056202
Purpose Trastuzumab and pertuzumab are human epidermal growth factor receptor 2 (HER2) -targeted monoclonal antibodies, and trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that combines the properties of trastuzumab with...
5.
Cox D, Allred A, Zhou Y, Infante J, Gordon M, Bendell J, et al.
Clin Pharmacol Drug Dev
. 2016 May;
4(4):287-94.
PMID: 27136909
Trametinib (Mekinist®) is a selective inhibitor of mitogen-activated protein kinase kinase (MEK) approved in the United States as a single agent and in combination with dabrafenib (Tafinlar®) for treatment of...
6.
Yardley D, Burris 3rd H, Peacock N, Raefsky E, Melnik M, Inhorn R, et al.
Breast Cancer Res Treat
. 2010 Jul;
123(2):471-5.
PMID: 20658263
nab-Paclitaxel has shown favorable efficacy and toxicity profiles compared to other taxanes in the treatment of metastatic breast cancer. In this pilot trial, we evaluated a nab-paclitaxel-containing adjuvant regimen in...
7.
Reece D, Sullivan D, Lonial S, Mohrbacher A, Chatta G, Shustik C, et al.
Cancer Chemother Pharmacol
. 2010 Mar;
67(1):57-67.
PMID: 20306195
Purpose: Characterize bortezomib pharmacokinetics/pharmacodynamics in relapsed myeloma patients after single and repeat intravenous administration at two doses. Methods: Forty-two patients were randomized to receive bortezomib 1.0 or 1.3 mg/m(2), days...
8.
Raza A, Galili N, Callander N, Ochoa L, Piro L, Emanuel P, et al.
J Hematol Oncol
. 2009 May;
2:20.
PMID: 19439093
Background: Ezatiostat hydrochloride liposomes for injection, a glutathione S-transferase P1-1 inhibitor, was evaluated in myelodysplastic syndrome (MDS). The objectives were to determine the safety, pharmacokinetics, and hematologic improvement (HI) rate....
9.
Dragovich T, Burris 3rd H, Loehrer P, Von Hoff D, Chow S, Stratton S, et al.
Am J Clin Oncol
. 2008 Apr;
31(2):157-62.
PMID: 18391600
Objectives: Cycloxygenase-2 (COX-2) is overexpressed in pancreatic tumors where it may be involved in inflammation, carcinogenesis, and the regulation of neoangiogenesis. The purpose of this trial was to evaluate the...
10.
Burris 3rd H, Rocha-Lima C
Oncologist
. 2008 Apr;
13(3):289-98.
PMID: 18378539
In advanced pancreatic cancer, single-agent gemcitabine became the standard therapy approximately 10 years ago. Subsequently, combinations of gemcitabine with fluorouracil, cisplatin, irinotecan, oxaliplatin, or pemetrexed produced no clear survival benefit....